hrp0097p1-423 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Craniosynostosis in hypophosphatasia

Pitea Marco , Sala Elisa , Ruggero Lanzafame , Crocè Ludovica , Mora Stefano

Hypophosphatasia (HPP) is a rare genetic disease caused by mutations with loss of function in the ALPL gene, which encodes for non-specific tissue alkaline phosphatase (TNSALP). We report a case of infantile hypophosphatasia. Due to positive family history for hypophosphatasia, a chorionic villus sampling was made, with evidence in composed heterozygous of variants c.407G>A and c.1489T>C in the ALPL gene. At birth the patient did not have clinical complications, however ...

hrp0089p2-p220 | GH & IGFs P2 | ESPE2018

The ZOMATRIP Study: Four Year Combination Therapy of GH and GnRHa in Girls with a Short Predicted Adult Height During Early Puberty: Adult Height Outcome

Dotremont Hilde , France Annick , Heinrichs Claudine , Tenoutasse Sylvie , Brachet Cecile , Cools Martine , De Waele Kathleen , Massa Guy , Lebrethon Marie-Christine , Gies Inge , Van Besien Jesse , Derycke Christine , De Schepper Jean , Rooman Raoul

Background: A combination of GH and a gonadotropin releasing hormone analogue (GnRH a) is hypothesized to improve adult height in children with a poor adult height prediction.Study design: In this multicenter study, 24 girls in early puberty (bone age ≤12.0 y),with a predicted adult height ≤151.0 cm and normal body proportions were treated with GH (Zomacton) 50 μg/kg per day and triptorelin (Gonapeptyl) 3.75 mg/month SC or IM (for 4 year...

hrp0084p2-535 | Puberty | ESPE2015

GH Deficiency with Advanced Bone Age: GHRH Receptor Mutation Detected by Exome Sequencing Associated to Non-Classical Congenital Adrenal Hyperplasia (CAH)

Correa Fernanda de Azevedo , Franca Marcela M , Fang Qing , Ma Qianyi , Bachega Tania A , Mendonca Berenice B , LJorge Alexander , Carvalho Luciani R , Camper Sally A , Arnhold Ivo J P

Background: Isolated Growth Hormone Deficiency (IGHD) is usually associated with a delayed bone age. A genetic cause for IGHD is more frequently found in patients with familial cases and/or consanguineous parents.Objective and hypotheses: To diagnose the genetic cause of IGHD and clarify the unusual clinical presentation of advanced bone age in one patient born to consanguineous parents.Method: Sanger sequencing of GH1, <e...

hrp0084fc8.1 | Obesity - Basic | ESPE2015

DLK1 Expression in Adipose Tissue Following Fetal Growth Restriction: Relation to Visceral Fat Expansion and Catch-Up Growth in Wistar Rats

Carreras-Badosa Gemma , Remesar Xavier , Prats-Puig Anna , Diaz-Roldan Ferran , Platero-Gutierrez Estibaliz , Martinez-Calcerrada Jose-Maria , de Zegher Francis , Ibanez Lourdes , Bassols Judit , Lopez-Bermejo Abel

Background: DLK1 (PREF1) is a key inhibitor of adipogenesis and adipocyte differentiation. Adipose tissue expansion depends on adequate adipocyte differentiation. However, whether lower DLK1 expression facilitates adipose tissue expansion following fetal growth restriction is so far unknown.Objective and hypotheses: To study the expression of DLK1 in the adipose tissue of prenatally growth-restricted rats and its relat...

hrp0084p3-1102 | Pituitary | ESPE2015

Clinical Characteristics of Children with Congenital Combined GH Deficiency without Associated Syndrome in Belgium

Zeevaert Renate , Verlinde Franciska , Thomas Muriel , De Zegher Francis , Cools Martine , Heinrichs Claudine , Beauloye Veronique , France Annick , Lebrethon Marie-Christine , Massa Guy

Background: Despite the fact that pituitary stalk interruption syndrome (PSIS) is a frequent finding in children with combined GH deficiency (CGHD), clinical data are still limited and the growth response to GH treatment has not been evaluated in comparison with CGDH with a normal stalk.Objective and hypotheses: To report the clinical and hormonal findings and evaluate the short term growth response to GH in Belgian children with congenital non-syndromat...

hrp0092p1-5 | Adrenals and HPA Axis | ESPE2019

18 years of neonatal screening for congenital adrenal hyperplasia in North-Eastern Italy: recall rate reduction thanks to liquid chromatograpy-tandem mass spectrometry as second tier test

cavarzere paolo , Palma Laura , Lauriola Silvana , Gaudino Rossella , Vincenzi Monica , Teofoli Francesca , Antoniazzi Franco , Camilot Marta

Background: In North-Eastern Italy, a newborn screening for congenital adrenal hyperlpasia (CAH) has been taking place since 2001 to diagnose the classical form of 21-hydroxylase deficiency (21-OHD). Thanks to the screening program based on 17-OHP levels in dried blood spots, early diagnosis of CAH is possible, allowing appropriate precocious treatment and reducing mortality rates. Unfortunately, a high false positive rate, especially in preterm, low-birth-wei...

hrp0089p2-p301 | Pituitary, Neuroendocrinology and Puberty P2 | ESPE2018

Efficacy and Safety of Triptorelin 3-Month Formulationin Patients with Central Precocious Puberty and BMI Evaluation.

Galli Francesca , Cavarzere Paolo , Ben Sarah Dal , Antoniazzi Franco , Gaudino Rossella

Background: Different formulations of gonadotropin-releasing hormone agonist (GnRHa) are available for the treatment of central precocious puberty (CPP). Currently there are few data on quarterly formulation depot (11.25 mg) during treatment.Aim: The purpose of this study is to analyse the effect of Triptorelin 11.25 mg 3-months depot in comparison with the monthly 3.75 mg formulation at the beginning and during the treatment of CPP.<p class="abstext...

hrp0089p2-p331 | Pituitary, Neuroendocrinology and Puberty P2 | ESPE2018

The Impact of Central Precious Puberty on Health-relatedqualityoflifeand Social, Emotive and Behavioral Competences Among Children Treated with GnRHa

Galli Francesca , Cavarzere Paolo , Ben Sarah Dal , Antoniazzi Franco , Gaudino Rossella

Background: Central precocious puberty (CPP) may affect quality of life (QOL) due to premature body and psychological changes that characterize this pathology. Few data are available on health-related quality of life (HRQOL) and social, emotive and behavioral competences in CPP children treated with gonadotropin-releasing hormone agonists (GnRHa). This study aimed to investigate these aspects in a group of CPP girls during therapy.Methods: Fifty-four CPP...

hrp0086p2-p500 | Fat Metabolism and Obesity P2 | ESPE2016

Prevalence and Characteristics of Polycystic Ovary Syndrome in Obese Adolescents

Ybarra Marina , Franco Ruth , Cominato Louise , Sampaio Raissa , Sucena Silvia , Damiani Durval

Background: Polycystic ovary syndrome (PCOS) in adolescence has a challenging diagnosis and therefore has raised intense discussions. Its prevalence in childbearing age women ranges from 5 to 10%. However, the prevalence in obese adolescents has not yet been reported. Besides, the relationship of PCOS with metabolic and cardiovascular disorders in this specific population has not been established.Objective and hypotheses: We aimed to assess the prevalenc...

hrp0082p2-d1-261 | Adrenals &amp; HP Axis | ESPE2014

Paradoxical Increase in Urinay Cortisol Excretion in Children with Primary Pigmented Nodular Adrenal Disease

Fraga Ana Beatriz , Anselmo Joao , Franco Catarina , Vaz Sara , Gomes Fernanda

Background: Pediatric Cushings syndrome is a rare condition and its diagnosis is always a challenge to the clinicians. The hypercortisolism can be classified as ACTH-dependent (Cushings disease) and ACTH-independent. The latter group comprises several hereditary conditions. One of them is primary pigmented nodular adrenocortical disease (PPNAD) which occurs isolated or as part of Carney complex (CNC). It is known that adult patients with Cushings syndrome due PPNAD exhibited a...